sicklecellanemianews5d
Study to compare SCD treatments for symptoms with a transplant
A University of Rochester hospital will open a patient study comparing the efficacy of SCD treatments to help families in ...
sicklecellanemianews9d
Living with a disability doesn’t mean we are worth less
In a society that often treats those living with a disability as "less than," columnist Mary Shaniqua reminds her community ...
sicklecellanemianews11d
Some beneficial lessons from living with sickle cell disease
For all of its challenges, living with sickle cell has offered columnist Oluwatosin Adesoye resilience, empathy, support, and ...
sicklecellanemianews9d
BEAM-101 gene-editing stem cell therapy shows promise in SCD
BEAM-101, a gene-editing stem cell therapy, showed early signs of efficacy among the first treated sickle cell patients in a ...
sicklecellanemianews3d
More stem cells for sickle cell gene therapy readied with motixafortide
It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than ...
sicklecellanemianews12d
AB Science gets European patent covering masitinib for SCD
AB Science said it received a notice of allowance from the European Patent Office for a patent covering the use of the experimental oral therapy masitinib to treat sickle cell disease (SCD). The ...
sicklecellanemianews17d
Oral AND017 granted orphan drug status for SCD
The U.S. Food and Drug Administration has granted orphan drug status to Kind Pharmaceuticals’ investigational oral small molecule AND017 to treat sickle cell disease (SCD). This designation is granted ...